IRVINE, Calif.--(BUSINESS WIRE)--March 6, 2006--Cortex Pharmaceuticals, Inc.'s (AMEX: COR), lead AMPAKINE(R) drug, CX717, showed positive results for the treatment of adults with Attention Deficit Hyperactivity Disorder (ADHD). Forty-nine patients with ADHD completed the randomized, double-blind, placebo-controlled, two-way crossover design performed at seven US sites. Cortex undertook this Phase IIa clinical trial to assess both the dose of drug required and the effectiveness of CX717 in an adult ADHD population. The primary outcome measure was the ADHD Rating Scale (ADHD-RS) which evaluates both the inattentiveness and hyperactivity symptoms. The overall ADHD-RS score showed a positive trend in the 800mg twice daily (bid) dose group (n = 22) with a statistically significant effect on the hyperactivity subscale (p=0.050) compared to placebo. The 200mg bid dose (n = 27) did not show a significant effect. CX717 was well tolerated, and there were no serious adverse events or other significant safety concerns with either dose. Further, no increases in blood pressure or heart rate were observed on either dose of CX717.
